后疫情时代血液系统恶性肿瘤或接受细胞治疗患者COVID-19管理建议:欧洲白血病感染会议(ECIL-10)
ECIL-10发布后疫情时代血液系统恶性肿瘤或接受细胞治疗患者COVID-19管理建议。诊断以鼻口咽拭子核酸检测为金标准,抗原检测阳性可快速决策但敏感性低。预防以主动免疫为核心,可能需每年匹配流行变异株;被动免疫用中和抗体因免疫逃逸变异株已失去指征。有症状患者早期抗病毒用奈玛特韦/利托那韦或瑞德西韦可能降低重症风险;重症-危重症推荐地塞米松或下调炎症细胞因子的药物(抗IL-6/抗IL-2药物、Janus激酶抑制剂)联合最佳支持与重症监护,免疫抑制患者需谨慎。COVID-19患者考虑推迟强化化疗、HCT预处理、T细胞免疫治疗或T细胞衔接抗体;无症状确诊患者推迟决策需个体化。
要点
- 有症状的血液肿瘤/细胞治疗患者COVID-19,早期抗病毒用奈玛特韦/利托那韦或瑞德西韦可能降低进展为重症-危重症风险。
- 重症-危重症COVID-19推荐地塞米松或下调炎症细胞因子的药物(抗IL-6/抗IL-2药物、Janus激酶抑制剂)联合最佳支持与重症监护,免疫抑制患者需谨慎。
- 核酸检测为诊断金标准;抗原检测阳性可快速决策但敏感性低,尤其无症状患者。
- 主动免疫是预防关键,可能需每年匹配流行变异株;中和抗体被动免疫因免疫逃逸变异株已失去指征。
- COVID-19患者考虑推迟强化化疗、HCT预处理、T细胞免疫治疗或T细胞衔接抗体;无症状确诊患者推迟决策个体化。
适用人群与场景
- 血液系统恶性肿瘤患者和/或接受造血细胞移植(HCT)的患者。
- 接受细胞治疗的患者。
诊断标准与关键阈值
- 鼻口咽拭子核酸检测病毒RNA为诊断金标准,因其高敏感性和特异性。
- 直接抗原检测阳性可快速管理决策,但敏感性低,尤其无症状患者。
处置流程与药物剂量
- 有症状患者早期抗病毒治疗用奈玛特韦/利托那韦或瑞德西韦,可能降低进展为重症-危重症COVID-19的风险。
- 对单药抗病毒治疗临床或病毒学失败的患者,考虑延长给药、重复疗程和联合抗病毒治疗。
- 重症-危重症COVID-19推荐地塞米松或下调炎症细胞因子反应的药物(抗IL-6/抗IL-2药物、Janus激酶抑制剂),联合最佳支持与重症监护,免疫抑制患者需谨慎。
- COVID-19患者考虑推迟强化化疗、HCT预处理、基于T细胞的免疫治疗或T细胞衔接抗体。
- 无症状确诊SARS-CoV-2感染患者的推迟决策按个案决定。
- 遵守接触和飞沫预防措施以避免传播,尤其疫情期间。
- 主动免疫是预防关键,可能需每年匹配流行变异株。
- 被动免疫用SARS-CoV-2中和抗体因免疫逃逸变异株出现已失去指征;恢复期血浆被提议用于被动免疫但多数中心不易获得。
研究设计与关键结果
- 制定机构:欧洲白血病感染会议(ECIL-10)。
- 方法:发布后疫情时代血液系统恶性肿瘤或接受细胞治疗患者COVID-19管理建议。
证据类型、等级与局限
- 证据类型:指南(欧洲白血病感染会议ECIL-10)。
- 局限:原文未报告局限性
对床旁实践的改变
- 有症状的血液肿瘤/细胞治疗患者COVID-19应早期抗病毒治疗,用奈玛特韦/利托那韦或瑞德西韦。
- 重症-危重症COVID-19使用地塞米松或抗炎药(抗IL-6/抗IL-2药物、Janus激酶抑制剂)联合最佳支持与重症监护,免疫抑制患者需谨慎。
- COVID-19患者考虑推迟强化化疗、HCT预处理、T细胞免疫治疗或T细胞衔接抗体;无症状确诊患者推迟决策个体化。
- 遵守接触和飞沫预防措施避免传播,尤其疫情期间。
- 主动免疫可能需每年匹配流行变异株;中和抗体被动免疫已失去指征。
指南或共识出处
- 欧洲白血病感染会议(ECIL-10)后疫情时代血液系统恶性肿瘤或接受细胞治疗患者COVID-19管理建议。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission, especially during epidemic waves. Detection of viral RNA by nucleic acid testing of naso-oro-pharyngeal samples is the gold standard for diagnosis due to its high sensitivity and specificity. Direct antigen testing allows for rapid management decisions if positive, but has a low sensitivity, especially in asymptomatic patients. Active immunisation is the key to prevention and may require annual matching to circulating variants. Passive immunization with SARS-CoV-2 neutralizing anti-antibodies lost its indication due to the emergence of immune escape variants. Convalescent plasma has been proposed for passive immunization but is not readily available in most centres. For symptomatic patients, early antiviral treatment with nirmatrelvir/ritonavir or remdesivir may reduce the risk of progression to severe-critical COVID-19. Prolonged administration, repeated courses, and a combination of antivirals are considered for patients with clinical or virological failure to antiviral monotherapy. In severe-critical COVID-19, dexamethasone or drugs downregulating the inflammatory cytokine responses (anti-Il-6/anti-IL-2 agents, Janus kinase inhibitor) are recommended, together with the best supportive and intensive care, but care should be exercised in immunosuppressed patients. Deferral of intensive chemotherapy, HCT conditioning, T-cell-based immunotherapy, or T-cell engaging antibodies are considered for patients with COVID-19, whereas deferral decisions are taken on a case-by-case basis for asymptomatic patients with confirmed SARS-CoV-2 infection.
参考来源
- Cesaro S, Ljungman P, Mikulska M, et al. Post-pandemic recommendations for the management of COVID-19 in patients with haematological malignancies or undergoing cellular therapy, from the European Conference on Infections in Leukaemia (ECIL-10). Leukemia. 2025. PMID: 40456838. doi:10.1038/s41375-025-02649-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。